PMID- 36517861 OWN - NLM STAT- MEDLINE DCOM- 20221216 LR - 20221222 IS - 1472-6963 (Electronic) IS - 1472-6963 (Linking) VI - 22 IP - 1 DP - 2022 Dec 14 TI - Costs associated with adverse events from remission induction for children with Acute Lymphoblastic Leukemia (ALL). PG - 1522 LID - 10.1186/s12913-022-08676-x [doi] LID - 1522 AB - BACKGROUND: ALL is the most frequent hematological tumor in children, so during remission induction chemotherapy protocol (RICP) adverse events (AEs) may appear. The public program in Mexico in charge of financial support to oncologic children without social security delivered a fix amount for ALL chemotherapy, but additional money needed to treat any other unexpected condition should be taken from the budget of the oncologic healthcare providers. So the purpose of our study was to estimate and evaluate the direct medical costs associated to EAs during RICP in children with ALL. METHODS: This study was retrospective, longitudinal, and observational based on medical records review of patients in RICP. The CTCAE was used to identify and classify AEs according to a SOC category. We focused on extracting resources data that were consumed both for inpatients and outpatients AEs. A micro-costing approach was adopted which involve quantification of each healthcare resource consumed by the hospital multiplying them by unit cost. The probability distributions of data were evaluated to identify the appropriated statistical tests to be used for comparisons between groups that were performed with Wilcoxon rank sum test. Generalized linear models (GLM) were adjusted to evaluate the effects of patient characteristics on total cost. RESULTS: Forty patients accumulated 204 inpatient and 81 outpatient AEs during RICP. Comparison of total costs between groups showed an incremental cost of $7,460.23 likewise attributable to AEs. The total cost of a pediatric patient undergoing RICP without adverse events was $3,078.36 and the total cost of a patient with AEs exceeds it threefold. CONCLUSIONS: The costs associated with AEs during RICP in Mexican children with ALL representing a high burden for the healthcare provider. Generalized linear models showed that variables such as sex, risk category and alive status are associated with the total costs of AEs. This is the first study aiming to analyze the effect of ALL-related AEs on health care costs in pediatric population, so our results may help not only to local decision making but also it may contribute to the research agenda in this field. CI - (c) 2022. The Author(s). FAU - Mejia-Arangure, Erendira AU - Mejia-Arangure E AD - Programa de Maestria y Doctorado en Ciencias Medicas, Odontologicas Y de La Salud, Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, Mexico. erenmejia@hotmail.com. AD - Medicina Basada en Evidencia, Unidad de Investigacion, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. erenmejia@hotmail.com. AD - , Dr. Marquez 162, Col. Doctores. Del. Cuauhtemoc, C.P. 06720, Ciudad de Mexico, Mexico. erenmejia@hotmail.com. FAU - Reyes-Lopez, Alfonso AU - Reyes-Lopez A AD - Centro de Estudios Economicos y Sociales en Salud, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Juarez-Villegas, Luis Enrique AU - Juarez-Villegas LE AD - Departamento de Oncologia Pediatrica, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Hernandez-Olivares, Yosef Olaf AU - Hernandez-Olivares YO AD - Centro de Estudios Economicos y Sociales en Salud, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Saucedo-Campos, Alberto Daniel AU - Saucedo-Campos AD AD - Departamento de Oncologia Pediatrica, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Hernandez-Pliego, Gabriela AU - Hernandez-Pliego G AD - Departamento de Oncologia Pediatrica, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Martinez-Valverde, Silvia AU - Martinez-Valverde S AD - Centro de Estudios Economicos y Sociales en Salud, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Barajas-Nava, Leticia A AU - Barajas-Nava LA AD - Medicina Basada en Evidencia, Unidad de Investigacion, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. FAU - Garduno-Espinosa, Juan AU - Garduno-Espinosa J AD - Direccion de Investigacion, Hospital Infantil de Mexico Federico Gomez, Ciudad de Mexico, Mexico. juan.gardunoe@gmail.com. LA - eng PT - Journal Article PT - Observational Study DEP - 20221214 PL - England TA - BMC Health Serv Res JT - BMC health services research JID - 101088677 SB - IM MH - Child MH - Humans MH - Retrospective Studies MH - *Health Care Costs MH - Budgets MH - Remission Induction MH - *Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy PMC - PMC9749331 OTO - NOTNLM OT - Adverse event OT - Chemotherapy OT - Children OT - Cost OT - Leukemia OT - Remission OT - Toxicity COIS- The authors declare that they have no competing interests. EDAT- 2022/12/15 06:00 MHDA- 2022/12/17 06:00 PMCR- 2022/12/14 CRDT- 2022/12/14 23:47 PHST- 2022/02/02 00:00 [received] PHST- 2022/10/10 00:00 [accepted] PHST- 2022/12/14 23:47 [entrez] PHST- 2022/12/15 06:00 [pubmed] PHST- 2022/12/17 06:00 [medline] PHST- 2022/12/14 00:00 [pmc-release] AID - 10.1186/s12913-022-08676-x [pii] AID - 8676 [pii] AID - 10.1186/s12913-022-08676-x [doi] PST - epublish SO - BMC Health Serv Res. 2022 Dec 14;22(1):1522. doi: 10.1186/s12913-022-08676-x.